Federal Health Official Walks Back Trump's Autism-Tylenol Link Claim
A top health official at the US Department of Health and Human Services has toned down his warning that taking Tylenol during pregnancy may be linked to autism in children. In a recent news conference, Secretary Robert F Kennedy Jr. acknowledged that while there are some studies suggesting a possible association between Tylenol and autism, these findings were not conclusive. "The causative association between Tylenol given in pregnancy and the perinatal periods is not sufficient to say it definitely causes autism," he said.
Kennedy's comments came after President Trump had made similar claims about the link between Tylenol and autism during pregnancy. In a September news conference, Trump stated that taking acetaminophen, commonly known as Tylenol, could be associated with an increased risk of autism in children. The US Health and Human Services Department later clarified that there was no scientific evidence to support this claim.
The revised stance by Kennedy has been welcomed by health experts who have long argued against the notion that Tylenol poses a significant risk to pregnant women or their developing babies. According to reputable health agencies, including the World Health Organization, no consistent association has been established between acetaminophen and autism despite extensive research.
Kennedy's comments are also seen as a step back from his previous claims about Tylenol and its alleged risks. In October, he claimed that anyone who takes Tylenol during pregnancy unless medically necessary is being irresponsible. His statements on male circumcision have also been widely criticized by medical experts.
The controversy surrounding Kennedy's claims has led to efforts to limit the availability of Tylenol in some states. However, health advocates argue that pregnant women should be advised to consult their healthcare provider before taking any medication, including acetaminophen. Johnson & Johnson and Kenvue, the companies behind the over-the-counter pain reliever, have denied claims that they engaged in deceptive marketing practices.
As the debate continues, Kennedy's revised stance serves as a reminder of the importance of relying on scientific evidence when making decisions about public health issues.
A top health official at the US Department of Health and Human Services has toned down his warning that taking Tylenol during pregnancy may be linked to autism in children. In a recent news conference, Secretary Robert F Kennedy Jr. acknowledged that while there are some studies suggesting a possible association between Tylenol and autism, these findings were not conclusive. "The causative association between Tylenol given in pregnancy and the perinatal periods is not sufficient to say it definitely causes autism," he said.
Kennedy's comments came after President Trump had made similar claims about the link between Tylenol and autism during pregnancy. In a September news conference, Trump stated that taking acetaminophen, commonly known as Tylenol, could be associated with an increased risk of autism in children. The US Health and Human Services Department later clarified that there was no scientific evidence to support this claim.
The revised stance by Kennedy has been welcomed by health experts who have long argued against the notion that Tylenol poses a significant risk to pregnant women or their developing babies. According to reputable health agencies, including the World Health Organization, no consistent association has been established between acetaminophen and autism despite extensive research.
Kennedy's comments are also seen as a step back from his previous claims about Tylenol and its alleged risks. In October, he claimed that anyone who takes Tylenol during pregnancy unless medically necessary is being irresponsible. His statements on male circumcision have also been widely criticized by medical experts.
The controversy surrounding Kennedy's claims has led to efforts to limit the availability of Tylenol in some states. However, health advocates argue that pregnant women should be advised to consult their healthcare provider before taking any medication, including acetaminophen. Johnson & Johnson and Kenvue, the companies behind the over-the-counter pain reliever, have denied claims that they engaged in deceptive marketing practices.
As the debate continues, Kennedy's revised stance serves as a reminder of the importance of relying on scientific evidence when making decisions about public health issues.